- Home
- CHWY vs BIIB Comparison
CHWY vs BIIB Comparison
Compare CHWY & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHWY
- BIIB
- Stock Information
- Founded
- CHWY 2010
- BIIB 1978
- Country
- CHWY United States
- BIIB United States
- Employees
- CHWY N/A
- BIIB N/A
- Industry
- CHWY Catalog/Specialty Distribution
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- CHWY Consumer Discretionary
- BIIB Health Care
- Exchange
- CHWY Nasdaq
- BIIB Nasdaq
- Market Cap
- CHWY 16.5B
- BIIB 18.7B
- IPO Year
- CHWY 2019
- BIIB 1991
- Fundamental
- Price
- CHWY $37.53
- BIIB $159.88
- Analyst Decision
- CHWY Strong Buy
- BIIB Buy
- Analyst Count
- CHWY 25
- BIIB 27
- Target Price
- CHWY $45.17
- BIIB $183.65
- AVG Volume (30 Days)
- CHWY 10.1M
- BIIB 1.9M
- Earning Date
- CHWY 09-10-2025
- BIIB 10-30-2025
- Dividend Yield
- CHWY N/A
- BIIB N/A
- EPS Growth
- CHWY N/A
- BIIB 31.67
- EPS
- CHWY 0.35
- BIIB 10.45
- Revenue
- CHWY $12,345,235,000.00
- BIIB $9,997,000,000.00
- Revenue This Year
- CHWY $8.77
- BIIB $2.00
- Revenue Next Year
- CHWY $7.09
- BIIB N/A
- P/E Ratio
- CHWY $107.45
- BIIB $15.29
- Revenue Growth
- CHWY 9.17
- BIIB 3.36
- 52 Week Low
- CHWY $26.28
- BIIB $110.04
- 52 Week High
- CHWY $48.62
- BIIB $194.13
- Technical
- Relative Strength Index (RSI)
- CHWY 44.81
- BIIB 74.24
- Support Level
- CHWY $36.92
- BIIB $135.39
- Resistance Level
- CHWY $40.55
- BIIB $140.67
- Average True Range (ATR)
- CHWY 1.29
- BIIB 4.32
- MACD
- CHWY 0.06
- BIIB 1.61
- Stochastic Oscillator
- CHWY 16.80
- BIIB 98.71
About CHWY Chewy Inc.
Chewy is the largest e-commerce petcare retailer in the US, generating $11.9 billion in fiscal 2024 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a stand-alone company in 2019 after spending a couple of years developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods like crates, leashes, and bowls.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.